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CANCER—Clinical Outcomes Studies
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OBJECTIVES: This study compares effectiveness of fotemustine
and dacarbazine in treatment of patients with malignant mela-
noma with or without brain metastases using a Quality Adjusted
Time Without Symptoms and Toxicity (Q-TWiST) integrating
efﬁcacy, safety and quality of life (QoL) into a composite measure
of effectiveness. METHODS: Clinical trial data from a published
study of fotemustine versus dacarbazine were used to partition
overall survival into time spent in speciﬁc health states including
toxicity, no progression and disease progression. Time spent with
toxicity or disease progression was weighted by an arbitrary
utility weight of 0.5. Survival analyses were conducted on the
partition components. Time spent with toxicity or brain
metastases was another analysis. Utilities were varied for sensi-
tivity analyses. RESULTS: The composite measure, taking into
account both efﬁcacy and safety, demonstrated that fotemustine
(N = 112) was signiﬁcantly more effective than dacarbazine
(N = 117), with an increase in quality-adjusted survival com-
pared with dacarbazine (7.35 versus 5.64 months; P = 0.044).
After taking into account time spent with toxicities, disease pro-
gression was avoided for an additional 1.54 months compared
with dacarbazine (P = 0.005), a gain that is clinically signiﬁcant
for patients with a life expectancy of 6 to 9 months. Additionally,
the mean quality-adjusted time to brain metastases was 15.39
months for the fotemustine treated patients compared to 7.04
months for the dacarbazine treated patients, for a gain of
8.35 months (P = 0.057). The quality-adjusted survival adjusting
for time spent with toxicity or with brain metastases also favored
treatment with fotemustine, 8.03 months versus 6.25 months
(P = 0.054). Sensitivity analyses demonstrated the results to be
robust. CONCLUSION: Q-TWiST analyses integrates efﬁcacy,
safety and QoL into a measure more appropriate for the assess-
ment of cancer treatment and conﬁrmed that fotemustine is
signiﬁcantly superior to dacarbazine, and provides a good alter-
native for the treatment of patients with malignant melanoma.
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OBJECTIVES: Tegafur with uracil (Uftoral) and capecitabine are
two oral ﬂuoropyrimidine therapies approved by NICE for the
treatment of ﬁrst-line metastatic colorectal cancer. One primary
difference between the tolerability proﬁles of the two oral treat-
ments is the incidence of hand and foot syndrome (HFS) which
occurs in patients treated with tegafur with uracil in less than 1%
of cases, and 57% overall for those treated with capeciabine
(17% grades 3/4). The primary objective of this research is to
describe the health resource utilisation associated with the inci-
dence of HFS in patients treated with capecitabine for colorectal
cancer. METHODS: This study is a retrospective chart review of
the management of HFS with a case vs. control, observational,
retrospective design. Information is collected from patient notes
by 50 oncologist treating colorectal cancer from across the UK.
Information on an overall sample of 600 patients will consist of
480 patients with HFS and 120 without. RESULTS: Interim
analyses of 277 patients are presented. This consists of 205
patients with HFS (74%) and 72 patients without HFS (26%).
55% of patients were male. Of the 205 patients with HFS,
18.5% of patients discontinued treatment, 45% of patients’
treatment was interrupted/ delayed and in 55% of patients the
dose had to be reduced. 43% of patients with HFS had a highest
grade of 3/4. For patients with HFS severity grade 3/4, 62%
experienced interruptions in treatment and 75% of patients had
their treatment discontinued. With regards overall health
resources utilised, there is a distinct trend reported of increased
resource use for increasing grade of severity of HFS versus
patients with no HFS. CONCLUSION: The preliminary results
of this UK research suggest that the incidence of HFS from
capecitabine treatment impacts a greater burden and resource
utilisation than otherwise expected.
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OBJECTIVES: This study examined care consumption and
management costs among patients who received second- or
third-line oral erlotinib therapy for non small-cell lung cancer
(NSCLC). METHODS: The study involved two observational
cohorts of NSCLC second- or third-line treated patients. In the
ﬁrst, created in 2005 (before erlotinib became available), the
patients received IV chemotherapy alone (IV cohort, 233
patients), while the patients in the second cohort, created in
2006, received oral erlotinib (oral cohort, 166 patients). Only
direct costs (payer’s perspective) were taken into account.
RESULTS: Treatment lasted a similar length during second-line
treatment but was signiﬁcantly longer in the oral cohort during
third-line therapy line (p < 0.008). The rate of conventional hos-
pitalization was not different between the two cohorts. In con-
trast, during 100 days of management, the patients in the oral
cohort tended to spend less time in hospital during second-line
treatment (p = 0.057), and the difference was statistically sig-
niﬁcant during third-line treatment (p < 0.05). Regardless of the
line of treatment, the oral cohort made signiﬁcantly fewer stays
in daycare clinics (p < 0.001), and received signiﬁcantly less
antiemetic treatment (p < 0.0001), erythropoietin (p < 0.005)
and G-CSF (p < 0.001), but required more treatment for skin
rash (p < 0.001). Monthly management costs per patient in the
IV and oral cohorts were respectively 3126 and 2750 euros
during second-line treatment and 3026 and 2823 euros during
third-line treatment (no signiﬁcant difference). A sensitivity
analysis showed that the results in the IV cohort were depen-
dent on the cost of chemotherapy. One limit of this study is that
transport costs were not taken into account. CONCLUSION: In
oral cohort, the cost of erlotinib is compensated by the reduc-
tion of daycare hospitalization costs and the limited cost of
adverse events medications. These results must be validated by
prospective observational studies focusing on quality of life and
the time spent in hospital.
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